

Estimate change	
TP change	
Rating change	

Bloomberg	LAXMIDEN IN
Equity Shares (m)	55
M.Cap.(INRb)/(USDb)	20.9 / 0.2
52-Week Range (INR)	584 / 308
1, 6, 12 Rel. Per (%)	-9/-16/-
12M Avg Val (INR M)	375

#### Financials & Valuations (INR b)

Y/E March	FY25	FY26E	FY27E
Sales (in billions)	2.4	3.0	3.7
EBITDA (in billions)	0.4	0.6	0.9
Adjusted PAT	0.3	0.5	0.7
EBITDA Margin (%)	17.5	20.9	24.4
Cons. Adj EPS (INR)	4.8	9.0	12.5
EPS Growth (%)	4.9	88.9	38.6
BV/Share (INR)	37.9	46.9	59.4
<b>Ratios</b>			
Net D-E	-0.4	-0.4	-0.4
RoE (%)	20.9	21.2	23.4
RoCE (%)	18.6	19.6	22.7
Payout (%)	0.0	0.0	0.0
<b>Valuations</b>			
P/E (x)	79.4	42.0	30.3
EV/EBITDA (x)	47.9	31.2	21.6
Div. Yield (%)	0.0	0.0	0.0
FCF Yield (%)	1.4	0.5	1.5
EV/Sales (x)	8.4	6.5	5.3

#### Shareholding Pattern (%)

As On	Jun-25	Mar-25
Promoter	41.7	41.7
DII	14.3	12.9
FII	33.6	34.2
Others	10.4	11.2

FII includes depository receipts

**CMP: INR380**

**TP: INR500 (+32%)**

**Buy**

#### Operationally in-line quarter

##### Digital push and scanner sales momentum to drive multi-year growth

- Laxmi Dental (LAXMIDEN) reported in-line revenue for the quarter, with EBITDA beating expectations by 7%. Earnings were also in line with estimates.
- Compared to the robust 20% revenue CAGR over FY23-25, 1QFY26 witnessed a temporary moderation in YoY revenue growth. That said, LAXMIDEN has a well-defined plan in place to maintain its growth trajectory on an annual basis.
- LAXMIDEN has been implementing measures to increase its digital presence in key focus markets. This is expected to not only enhance engagement within its dentist network but also support the marketing of additional products, such as aligners, through the same channel.
- Compared to 250 scanners sold in FY25, LAXMIDEN sold over 200 scanners in 1QFY26 and targets to sell over 1,000 scanners in FY26.
- Industry tailwinds remain strong for the aligners business, and LAXMIDEN is well-positioned to benefit from them, given its established relationship with dentists and its end-to-end manufacturing capabilities. The company continues to expand its presence across Tier I/II cities and is steadily increasing business from its existing dentist network.
- We largely maintain our estimates for FY26/FY27. We value LAXMIDEN at 40x 12M forward earnings to arrive at a TP of INR500.
- We expect 24%/47%/68% revenue/EBITDA/PAT CAGR over FY25-27, led by a) increased traction driven by a higher digital reach, b) CE approval for its kid-e-dental product, c) higher registration in newer geographies, and d) better operating leverage. Reiterate BUY.

##### Lower revenue and operating leverage drag EBITDA and PAT for 1QFY26

- LAXMIDEN's 1QFY26 revenue grew 10% YoY to INR656m (in-line).
- Laboratory offering sales grew 14% YoY to INR444m. The International business grew 12% YoY to INR176m, while the domestic business grew 4.4% YoY to INR210m. Within lab offerings for the domestic/international segment, scanner sales grew 93% YoY to INR58m.
- Aligner solution sales grew 7% YoY to INR186m. Within aligners, the Bizdent business grew 3.3% YoY to INR93m. The Vedia business grew 37% YoY to INR92m.
- Gross Margin (GM) contracted 260bp YoY to 73.3% due to an increase in raw material costs (down 260bp YoY).
- EBITDA margin contracted 530bp YoY to 18.2% (our est: 17%), largely due to a contraction in GM, supported by increased employee expenses (820bp YoY each as a % of sales).
- As a result, EBITDA declined 15% YoY to INR119m (our est: INR112m).
- Kids-e-dental's 1QFY26 revenue stood at INR44m, down 48% YoY.

- PAT declined 21% YoY to INR83m (in line) due to ESOP as well as a decline in Kids-e-dental's revenue.

### Highlights from the management commentary

- While revenue grew 10% YoY in 1QFY26, management remains confident of achieving 20-25% YoY growth for FY26.
- LAXMIDEN has sold over 200 scanners in 1QFY26; it aims to sell over 1,000 scanners during FY26.
- Delays in regulatory approvals impacted the performance of Kids-e-dental. However, LAXMIDEN expects growth in this segment to pick up from 2QFY26/3QFY26.
- Through its investments in AI Dent, LAXMIDEN aims to offer AI-powered solutions—such as dental imaging, X-ray analysis software, and other AI-driven dentistry tools—to existing customers. These additions are expected to further enhance the value proposition of its current offerings.

#### Quarterly perf. (Consol.)

Y/E March	FY25				FY26E				FY25	FY26E	FY26E	
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q			1QE	vs Est
<b>Net Sales</b>	<b>597</b>	<b>571</b>	<b>617</b>	<b>607</b>	<b>656</b>	<b>714</b>	<b>802</b>	<b>877</b>	<b>2,391</b>	<b>3,049</b>	<b>656</b>	<b>0.0%</b>
YoY Change (%)	N/A	N/A	29.0	10.2	9.9	25.0	30.0	44.6	23.5	27.5	10	
Total Expenditure	457	484	520	511	537	578	623	674	1,972	2,412	545	
<b>EBITDA</b>	<b>140</b>	<b>87</b>	<b>96</b>	<b>95</b>	<b>119</b>	<b>136</b>	<b>179</b>	<b>204</b>	<b>419</b>	<b>637</b>	<b>112</b>	<b>6.7%</b>
YoY Change (%)	N/A	N/A	144.7	-18.5	-15.0	55.5	85.9	113.9	76.1	52.2	-20	
Margins (%)	23.5	15.3	15.6	15.7	18.2	19.0	22.3	23.2	17.5	20.9	17	115.0
Depreciation	34	34	40	43	36	48	52	64	150	200	45	
<b>EBIT</b>	<b>106</b>	<b>53</b>	<b>57</b>	<b>52</b>	<b>83</b>	<b>88</b>	<b>127</b>	<b>139</b>	<b>269</b>	<b>437</b>	<b>67</b>	<b>25.2%</b>
YoY Change (%)	N/A	N/A	728.8	-38.0	-21.7	64.6	123.9	166.5	126.7	62.7	-37	
Interest	14	12	15	13	5	3	2	-7	54	3	6	
Other Income	4	7	6	16	17	20	22	25	33	84	18	
<b>PBT before EO expense</b>	<b>96</b>	<b>49</b>	<b>47</b>	<b>56</b>	<b>96</b>	<b>105</b>	<b>147</b>	<b>171</b>	<b>248</b>	<b>518</b>	<b>79</b>	<b>22.1%</b>
Extra-Ord expense	-59	0	0	-4	0	0	0	0	-70	0	0	
<b>PBT</b>	<b>155</b>	<b>49</b>	<b>47</b>	<b>60</b>	<b>96</b>	<b>105</b>	<b>147</b>	<b>171</b>	<b>318</b>	<b>518</b>	<b>79</b>	<b>22.1%</b>
Tax	18	11	11	25	23	24	34	25	65	107	16	
Rate (%)	11.4	23.3	22.7	41.2	23.8	23.0	23.5	14.8	20.3	20.6	21	
MI & P/L of Asso. Cos.	-20	-22	-12	-8	10	22	22	29	64	83	21	
<b>Reported PAT</b>	<b>157</b>	<b>59</b>	<b>48</b>	<b>43</b>	<b>83</b>	<b>102</b>	<b>134</b>	<b>174</b>	<b>318</b>	<b>494</b>	<b>83</b>	<b>-0.4%</b>
<b>Adj PAT</b>	<b>105</b>	<b>59</b>	<b>48</b>	<b>40</b>	<b>83</b>	<b>102</b>	<b>134</b>	<b>174</b>	<b>262</b>	<b>494</b>	<b>83</b>	<b>-0.4%</b>
YoY Change (%)	N/A	N/A	133.2	-51.0	-21.3	73.3	178.7	331.7	4.9	88.9	-21	
Margins (%)	17.6	10.3	7.8	6.7	12.6	14.3	16.7	19.9	10.9	16.2	13	

E: MOFSL Estimates



## Conference call highlights

- By converting physical reach into digital reach, LAXMIDEN aims to channel both its laboratory solutions and aligners through its dentist network.
- Delays in regulatory approvals impacted the performance of Kids-e-dental. LAXMIDEN expects growth in this segment to pick up from 2QFY26/3QFY26.
- LAXMIDEN was successful in passing earlier 10% US tariff to its customers. It is discussing with customers for the subsequent tariff increase effect. Notably, the competing country also has similar tariff from US and hence, there is very limited pricing disruption impact on the exports business of LAXMIDEN.
- The company plans to diversify geography-specific risks by expanding its offerings in other countries.
- Biz-Dent revenue was largely stable at INR93m for the quarter, while Vedia's revenue posted strong 37% YoY growth to INR92m.
- Almost 55% of the company's Indian business revenue comes from Tier-1 cities, while 34%/11% comes from Tier-II/III cities.

## Stable domestic labs; resilient international sales amid tariff impact


- LAXMIDEN's 10% YoY growth % for the quarter was a breather after three years of robust 20%+ growth in revenue.
- Domestic lab offerings were stable on a YoY basis. Excluding one-time products in 1QFY25, YoY growth in domestic lab offerings would be 10.5% YoY, partly due to seasonality. 2H is typically expected to be better than 1H of the financial year.
- International lab offering sales grew 12% YoY for the quarter compared to 38% YoY growth in FY25. US tariff-related aspects led to renegotiations, with customers temporarily impacting business over the near term. In fact, the 10% tariff imposed in Apr'25 has been passed on to customers, reflecting the strong quality of LAXMIDEN's lab offerings and their acceptability by customers.
- LAXMIDEN delivered a strong performance in the Vedia segment within aligners for the quarter, led by improved visibility from the IDS exhibition. This implies sustained growth momentum in the coming quarters.
- However, this benefit was offset to some extent by stable sales in the B2B2C business (Bizdent). LAXMIDEN continues to focus on improving customer service, widen its reach in Tier II/III cities, and revive growth in near-to-medium term.
- LAXMIDEN is awaiting CE approval for the scale up of the Kids-e-dental business.

## Reiterate BUY


- We largely maintain our estimates for FY26/FY27. We value LAXMIDEN at 40x 12M forward earnings to arrive at a TP of INR500.
- We expect 24%/47%/68% revenue/EBITDA/PAT CAGR over FY25-27, led by a) increased traction driven by a higher digital reach, b) CE approval for its kid-e-dental product, c) higher registration in newer geographies, and d) better operating leverage. Reiterate BUY.

## Story in charts


### Exhibit 1: Expect revenue CAGR of 24% over FY25-27




### Exhibit 2: Gross margin to expand 90bp over FY25-27




### Exhibit 3: EBITDA margin to expand 690bp over FY25-27




### Exhibit 4: PAT margins to expand 760bp over FY25-27



### Exhibit 5: ROE to expand 250bp over FY25-27



### Exhibit 6: Revenue breakup for 1QFY26



## Financials and valuations

Consolidated - Income Statement							(INR Million)
Y/E March	FY22	FY23	FY24	FY25	FY26E	FY27E	
<b>Total Income from Operations</b>	<b>1,368</b>	<b>1,616</b>	<b>1,936</b>	<b>2,391</b>	<b>3,049</b>	<b>3,699</b>	
Change (%)	NA	18.1	19.8	23.5	27.5	21.3	
Raw Materials	397	418	485	572	713	851	
Employees Cost	531	653	715	845	1,009	1,147	
Other Expenses	387	455	498	555	689	799	
<b>Total Expenditure</b>	<b>1,314</b>	<b>1,527</b>	<b>1,698</b>	<b>1,972</b>	<b>2,412</b>	<b>2,796</b>	
% of Sales	96.0	94.5	87.7	82.5	79.1	75.6	
<b>EBITDA</b>	<b>54</b>	<b>90</b>	<b>238</b>	<b>419</b>	<b>637</b>	<b>903</b>	
Margin (%)	4.0	5.5	12.3	17.5	20.9	24.4	
Depreciation	84	110	119	150	200	264	
<b>EBIT</b>	<b>-30</b>	<b>-20</b>	<b>119</b>	<b>269</b>	<b>437</b>	<b>639</b>	
Int. and Finance Charges	36	41	50	54	3	1	
Other Income	12	22	17	33	84	107	
<b>PBT bef. EO Exp.</b>	<b>-53</b>	<b>-39</b>	<b>86</b>	<b>248</b>	<b>518</b>	<b>745</b>	
EO Items	-110	-1	-1	70	0	0	
<b>PBT after EO Exp.</b>	<b>-163</b>	<b>-40</b>	<b>85</b>	<b>318</b>	<b>518</b>	<b>745</b>	
Total Tax	24	2	-94	65	107	155	
Tax Rate (%)	-14.5	-4.7	-110.5	20.3	20.6	20.8	
Minority Interest	-3	-2	5	1	-1	0	
Share of profit in JV/associate	-1	6	89	72	82	95	
loss from disc operations	0	0	-16	-7	0	0	
<b>Reported PAT</b>	<b>-184</b>	<b>-40</b>	<b>248</b>	<b>318</b>	<b>494</b>	<b>685</b>	
<b>Adjusted PAT</b>	<b>-58</b>	<b>-39</b>	<b>250</b>	<b>262</b>	<b>494</b>	<b>685</b>	
Change (%)	NA	-32.5	-738.9	4.9	88.9	38.6	
Margin (%)	-4.2	-2.4	12.9	10.9	16.2	18.5	

Consolidated - Balance Sheet							(INR Million)
Y/E March	FY22	FY23	FY24	FY25	FY26E	FY27E	
Equity Share Capital	3	3	3	110	110	110	
Total Reserves	208	175	422	1,975	2,470	3,155	
<b>Net Worth</b>	<b>211</b>	<b>178</b>	<b>425</b>	<b>2,085</b>	<b>2,580</b>	<b>3,265</b>	
Minority Interest	19	17	21	2	2	2	
Total Loans	387	387	498	195	20	10	
Deferred Tax Liabilities	-1	-2	-109	-109	-109	-109	
<b>Capital Employed</b>	<b>615</b>	<b>580</b>	<b>835</b>	<b>2,173</b>	<b>2,493</b>	<b>3,168</b>	
Gross Block	417	519	690	893	1,193	1,513	
Less: Accum. Deprn.	30	137	253	404	604	868	
<b>Net Fixed Assets</b>	<b>387</b>	<b>382</b>	<b>436</b>	<b>489</b>	<b>589</b>	<b>645</b>	
<b>Total Investments</b>	<b>35</b>	<b>40</b>	<b>129</b>	<b>104</b>	<b>104</b>	<b>104</b>	
<b>Curr. Assets, Loans&amp;Adv.</b>	<b>604</b>	<b>547</b>	<b>708</b>	<b>2,252</b>	<b>2,720</b>	<b>3,535</b>	
Inventory	295	242	247	187	301	375	
Account Receivables	204	204	249	367	484	608	
Cash and Bank Balance	11	10	7	908	926	1,328	
Loans and Advances	95	91	204	791	1,009	1,224	
<b>Curr. Liability &amp; Prov.</b>	<b>411</b>	<b>388</b>	<b>439</b>	<b>672</b>	<b>920</b>	<b>1,117</b>	
Account Payables	266	225	158	321	484	598	
Other Current Liabilities	115	127	239	305	389	472	
Provisions	30	36	42	47	47	47	
<b>Net Current Assets</b>	<b>193</b>	<b>159</b>	<b>269</b>	<b>1,580</b>	<b>1,800</b>	<b>2,419</b>	
<b>Appl. of Funds</b>	<b>615</b>	<b>580</b>	<b>835</b>	<b>2,173</b>	<b>2,492</b>	<b>3,168</b>	

## Financials and valuations

### Ratios

Y/E March	FY22	FY23	FY24	FY25	FY26E	FY27E
<b>Basic (INR)</b>						
<b>EPS</b>	<b>-1.1</b>	<b>-0.7</b>	<b>4.5</b>	<b>4.8</b>	<b>9.0</b>	<b>12.5</b>
Cash EPS	17.0	46.0	239.6	7.5	12.6	17.3
BV/Share	136.8	115.5	275.7	37.9	46.9	59.4
DPS	0.0	0.0	0.0	0.0	0.0	0.0
Payout (%)	0.0	0.0	0.0	0.0	0.0	0.0
<b>Valuation (x)</b>						
P/E	NA	NA	83.2	79.4	42.0	30.3
Cash P/E	22.3	8.2	1.6	50.4	29.9	21.9
P/BV	2.8	3.3	1.4	10.0	8.1	6.4
EV/Sales	0.7	0.6	0.6	8.4	6.5	5.3
EV/EBITDA	17.7	10.7	4.5	47.9	31.2	21.6
Dividend Yield (%)	0.0	0.0	0.0	0.0	0.0	0.0
FCF per share	-2.4	34.9	-10.9	5.2	2.0	5.6
<b>Return Ratios (%)</b>						
RoE	-54.9	-20.1	82.8	20.9	21.2	23.4
RoCE	-6.7	1.4	63.5	18.6	19.6	22.7
RoIC	-12.0	-3.9	40.6	23.0	26.4	31.6
<b>Working Capital Ratios</b>						
Fixed Asset Turnover (x)	3.3	3.1	2.8	2.7	2.6	2.4
Asset Turnover (x)	2.2	2.8	2.3	1.1	1.2	1.2
Inventory (Days)	79	55	47	28	36	37
Debtor (Days)	54	46	47	56	58	60
Creditor (Days)	71	51	30	49	58	59
<b>Leverage Ratio (x)</b>						
Current Ratio	1.5	1.4	1.6	3.4	3.0	3.2
Interest Cover Ratio	-0.8	-0.5	2.4	5.0	150.4	1,242.4
Net Debt/Equity	1.6	1.9	0.9	-0.4	-0.4	-0.4

### Consolidated - Cash Flow Statement

Y/E March	FY22	FY23	FY24	FY25	FY26E	FY27E
OP/(Loss) before Tax	-162	-46	69	310	600	840
Depreciation	84	110	120	150	200	264
Interest & Finance Charges	33	39	48	40	-81	-107
Direct Taxes Paid	0	-3	-10	-25	-107	-155
(Inc)/Dec in WC	-90	44	-119	19	-202	-216
<b>CF from Operations</b>	<b>-135</b>	<b>145</b>	<b>107</b>	<b>494</b>	<b>411</b>	<b>626</b>
Others	115	4	11	-56	0	0
<b>CF from Operating incl EO</b>	<b>-20</b>	<b>149</b>	<b>118</b>	<b>438</b>	<b>411</b>	<b>626</b>
(Inc)/Dec in FA	16	-95	-135	-153	-300	-320
<b>Free Cash Flow</b>	<b>-4</b>	<b>54</b>	<b>-17</b>	<b>285</b>	<b>111</b>	<b>306</b>
(Pur)/Sale of Investments	0	-4	0	-15	0	0
Others	14	5	-10	-124	84	107
<b>CF from Investments</b>	<b>30</b>	<b>-94</b>	<b>-144</b>	<b>-292</b>	<b>-216</b>	<b>-213</b>
Issue of Shares	15	0	0	1,380	0	0
Inc/(Dec) in Debt	-20	22	23	-134	-175	-10
Interest Paid	-36	-41	-50	-54	-3	-1
Dividend Paid	0	0	0	0	0	0
Others	0	0	0	-86	1	0
<b>CF from Fin. Activity</b>	<b>-40</b>	<b>-19</b>	<b>-27</b>	<b>1,106</b>	<b>-177</b>	<b>-11</b>
<b>Inc/Dec of Cash</b>	<b>-30</b>	<b>36</b>	<b>-53</b>	<b>1,252</b>	<b>18</b>	<b>403</b>
Opening Balance	-109	10	10	7	908	926
Others	149	-36	50	-351	0	0
<b>Closing Balance</b>	<b>10</b>	<b>10</b>	<b>7</b>	<b>908</b>	<b>926</b>	<b>1,328</b>

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

#### Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on [www.motilaloswal.com](http://www.motilaloswal.com). MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at [www.nseindia.com](http://www.nseindia.com), [www.bseindia.com](http://www.bseindia.com). Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

#### Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

#### For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

#### For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

#### For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to [grievances@motilaloswal.com](mailto:grievances@motilaloswal.com).

Nainesh Rajani

Email: [nainesh.rajan@motilaloswal.com](mailto:nainesh.rajan@motilaloswal.com)

Contact: (+65) 8328 0276

#### Specific Disclosures

1. Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies).  
MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.  
Nature of Financial interest is holding equity shares or derivatives of the subject company
2. Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.  
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report:No
3. Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.  
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
4. Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.  
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
5. Research Analyst has not served as an officer, director or employee of subject company(ies).

6. MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
7. MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
10. MOFSL has not engaged in market making activity for the subject company.

---

The associates of MOFSL may have:

financial interest in the subject company

actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.

received compensation/other benefits from the subject company in the past 12 months

any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

acted as a manager or co-manager of public offering of securities of the subject company in past 12 months

be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)

received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.

Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

#### Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

#### Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

#### Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alterations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263;

www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

#### Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrivances@motilaloswal.com.